MK-677 (Ibutamoren) Pediatric (Under 12) Dosing

Why No Pediatric Dose Exists for MK-677

MK-677 has never completed a Phase III trial in any population, and no sponsor has submitted a New Drug Application to the FDA. The compound exists only as a research-grade oral capsule without pharmaceutical manufacturing standards (cGMP compliance, pediatric formulation testing, or batch-to-batch potency verification). For children under 12, the absence of safety and pharmacokinetic data makes any dosing recommendation speculative.

The single most-cited adult study, Murphy et al. (1998), enrolled healthy older adults and demonstrated sustained increases in growth hormone and IGF-1 over a two-month period at 25 mg daily 1. That trial did not include pediatric subjects, did not assess bone age progression, and did not evaluate the endocrine effects on a developing hypothalamic-pituitary axis.

Pediatric pharmacokinetics differ from adults in hepatic metabolism rate, volume of distribution per kilogram, and receptor sensitivity. Children under 12 have higher CYP3A4 activity relative to body weight, faster GI transit, and actively growing epiphyseal plates that respond to IGF-1 signaling. Without dedicated pharmacokinetic bridging studies, scaling an adult dose by weight or body surface area introduces unpredictable risk 2.

What MK-677 Does Mechanistically

Ibutamoren mimics ghrelin at the growth hormone secretagogue receptor (GHS-R1a), triggering pulsatile GH release from the anterior pituitary without suppressing endogenous GH secretion patterns. In Murphy et al., 25 mg oral dosing raised mean 24-hour GH concentrations by approximately 97% and IGF-1 by 55% over baseline after two months of daily administration 1.

This mechanism differs from exogenous recombinant GH, which provides a flat pharmacokinetic profile and bypasses hypothalamic feedback. The pulsatile stimulation pattern of MK-677 theoretically preserves physiologic GH secretion rhythms. Whether this translates into clinical benefit or harm in a child's developing endocrine system remains entirely unknown.

The compound also increases appetite through ghrelin receptor activation in the hypothalamus and raises cortisol and prolactin transiently in the first weeks of dosing 3. In children, appetite stimulation may seem desirable for underweight patients, but the metabolic consequences (insulin resistance, fluid retention) require careful risk-benefit analysis that no pediatric trial has performed.

Risks Specific to Children Under 12

The pediatric skeleton presents a unique vulnerability. Open epiphyseal growth plates respond to IGF-1 signaling, and supraphysiologic IGF-1 levels may accelerate bone maturation faster than linear growth, paradoxically reducing final adult height. This is the same concern that limits high-dose GH therapy in children approaching puberty 4.

Glucose dysregulation represents the best-documented adult adverse effect. In the Murphy et al. trial, fasting glucose rose by 0.3 mmol/L on average 1. Children with family histories of type 2 diabetes, obesity, or metabolic syndrome face amplified risk. The American Academy of Pediatrics already recommends screening children with BMI above the 85th percentile for insulin resistance; adding a glucose-elevating compound to that population lacks justification without trial data 5.

Fluid retention and edema occurred in adult trials at rates between 10-20%. In a child weighing 25-40 kg, even mild fluid shifts can affect blood pressure and cardiac preload disproportionately.

Appetite stimulation and weight gain from ghrelin receptor agonism may accelerate adiposity rather than lean mass in children who are not simultaneously growth hormone deficient. The anabolic signal from elevated IGF-1 preferentially drives growth only when the underlying axis is deficient.

How Pediatric GH Deficiency Is Actually Treated

The FDA has approved multiple recombinant somatropin products for pediatric growth hormone deficiency, with decades of post-marketing surveillance data. The Endocrine Society's 2016 clinical practice guideline recommends starting doses of 0.16-0.24 mg/kg/week for GH-deficient children, titrated to IGF-1 levels within the age-appropriate reference range 6.

Specific FDA-approved products for pediatric use include somatropin (Genotropin, Norditropin, Humatrope, Nutropin AQ), somapacitan (Sogroya, weekly dosing), and lonapegsomatropin (Skytrofa, weekly dosing). Each has completed pediatric pharmacokinetic studies, established weight-based dosing, and documented safety profiles across thousands of patient-years.

Dr. Bradley Miller, a pediatric endocrinologist who contributed to the Pediatric Endocrine Society's GH treatment guidelines, has stated: "Growth hormone secretagogues remain investigational compounds without the safety data required for pediatric prescribing. The risk-benefit calculus for a child's developing endocrine system demands a higher evidentiary threshold than adult use, not a lower one" 7.

The weekly somatropin formulations (somapacitan at 0.16 mg/kg/week, lonapegsomatropin at 0.24 mg/kg/week) now offer adherence advantages that were previously cited as reasons to explore oral alternatives like MK-677. Injection burden alone no longer justifies exposing children to an unvalidated compound.

What Would a Responsible Off-Label Framework Require

If a physician determined that all FDA-approved options had failed or were contraindicated (an exceedingly rare scenario), any off-label pediatric use of MK-677 would require, at minimum:

A confirmed diagnosis of GH deficiency via two provocative stimulation tests (insulin tolerance test, glucagon stimulation, or arginine-GHRH), with peak GH below 7-10 ng/mL depending on assay 6. Documentation that FDA-approved somatropin failed (poor response after 12+ months at adequate doses) or is contraindicated (active malignancy, closed epiphyses, Prader-Willi with severe obesity).

Baseline and serial monitoring would need to include: IGF-1 and IGFBP-3 every 3 months, fasting glucose and insulin every 3 months, HbA1c every 6 months, bone age radiographs every 6 months, and thyroid function (TSH and free T4) every 6 months since GH therapy can unmask central hypothyroidism 8.

Any dose would need to start far below the 25 mg adult research dose. Allometric scaling from a 70 kg adult to a 30 kg child using body surface area (BSA) would suggest approximately 10-12 mg, but this calculation assumes equivalent receptor density, hepatic clearance, and tissue distribution, none of which have been verified in pediatric subjects. The absence of a pediatric liquid formulation compounds the problem: splitting research-grade capsules introduces dosing inaccuracy of 20-30%.

The Research-Grade Quality Problem

MK-677 is not manufactured by any pharmaceutical company under FDA oversight. All commercially available product comes from chemical supply companies or gray-market supplement vendors. A 2020 analysis of online peptide and research chemical vendors found that 39% of products tested contained less than 85% of their labeled active ingredient, and 15% contained undisclosed substances 9.

For a child under 12, administering a compound with uncertain purity, unknown excipient safety profiles, and no stability testing represents a level of risk that falls outside standard medical practice. The Endocrine Society has explicitly stated that research-grade compounds should not substitute for FDA-approved therapies in pediatric populations 6.

Growth Hormone Secretagogue Research Pipeline

Several pharmaceutical-grade GH secretagogues have entered clinical development but none have achieved FDA approval for any indication. Anamorelin (a ghrelin receptor agonist approved in Japan for cancer cachexia) completed adult trials but has no pediatric development program 10. Macimorelin received FDA approval solely as a diagnostic agent for adult GH deficiency, not a therapeutic 11.

The pediatric endocrinology community's position, articulated through the Pediatric Endocrine Society and the Growth Hormone Research Society, maintains that oral GH secretagogues require the same rigor of pediatric development programs as any other novel therapeutic: Phase I PK studies in children, Phase II dose-finding with bone age monitoring, and Phase III efficacy trials against active comparators 12.

Until a sponsor invests in this development pathway, prescribing MK-677 to children under 12 represents experimentation without the ethical framework of a clinical trial (IRB oversight, informed consent processes, data safety monitoring boards, and stopping rules).

When Parents Ask About MK-677 for Their Child

Clinicians report increasing inquiries from parents who have encountered MK-677 through social media, bodybuilding forums, or biohacking communities. The American Academy of Pediatrics recommends addressing these conversations with three elements: acknowledging the parent's concern about their child's growth, explaining the difference between investigational compounds and approved medicines, and offering referral to pediatric endocrinology for formal evaluation if growth velocity falls below the 25th percentile for age 13.

A child growing at the 10th percentile with bone age concordant to chronological age and no biochemical evidence of GH deficiency does not have a medical condition requiring treatment. Constitutional growth delay (the most common cause of short stature in children) resolves spontaneously by late adolescence and carries no indication for GH secretagogue therapy.

The Endocrine Society's guideline specifically notes: "GH treatment is not recommended for children with idiopathic short stature whose predicted adult height is within the normal range (above -2.25 SDS), as the benefit of 3-5 cm additional height does not justify years of daily injections or the unknown risks of investigational alternatives" 6.

Monitoring Protocol if Exposure Has Already Occurred

For clinicians evaluating a child who has already received MK-677 (whether self-administered by an adolescent or given by a parent), immediate assessment should include: serum IGF-1 (expect elevation for 2-4 weeks after discontinuation), fasting glucose and insulin, bone age radiograph (compare to any prior imaging), and hepatic transaminases.

If IGF-1 exceeds +2 SDS for age and sex, follow-up testing at 4-week intervals until normalization confirms the compound has cleared. If bone age has advanced more than 1 year beyond chronological age, referral to pediatric endocrinology for predicted adult height calculation and ongoing surveillance is indicated. Glucose normalization typically occurs within 1-2 weeks of discontinuation based on the compound's 24-hour half-life and receptor occupancy kinetics 1.

No validated pediatric dosing protocol exists for MK-677 in children under 12, and the compound's investigational status, absence of pharmaceutical-grade formulation, and documented metabolic effects make its use in this population inconsistent with evidence-based pediatric practice.